Some relevant excerpts:
The study tested whether Vytorin was better than Zocor alone at limiting plaque buildup in the arteries of 720 people with super-high cholesterol because of a gene disorder.
The results show the drug had "no result - zilch. In no subgroup, in no segment, was there any added benefit" for reducing plaque, said Dr. John Kastelein, the Dutch scientist who led the study.
The New England Journal also published a report showing that Vytorin and Zetia's use soared in the U.S. amid a $200 million advertising blitz. In Canada, where marketing drugs directly to consumers is not allowed, sales only about one-fourth as strong.
Two congressional panels launched probes into why it took drugmakers nearly two years after the study's completion to release results.